E-drug: GlaxoSmithKline and WHO sign agreement
cross posted from Afronets with thanks.
Source: International Public HealthWatch
Press Release WHO/10 2 March 2001
GLAXOSMITHKLINE AND WORLD HEALTH ORGANIZATION SIGN AGREEMENT TO
DEVELOP A NEW TREATMENT FOR MALARIA
GlaxoSmithKline and the World Health Organization (WHO) today
announce that they have signed an agreement for the development of a
new treatment for malaria called LAPDAP.
LAPDAP, a product that combines two existing anti-malarial compounds
chlorproguanil and dapsone, is a potential life-saving medicine. The
aim of the agreement is to develop LAPDAP as an effective oral
treatment for uncomplicated malaria, primarily for use in Sub-Saharan
Africa, but also in other regions of the world where this may be
appropriate. To date, clinical trials in Sub-Saharan Africa have
demonstrated that LAPDAP is effective in the treatment of
uncomplicated malaria including malaria resistant to other standard
first line therapies such as chloroquine and
LAPDAP will be made available at a preferential price for public
health programmes. The medicine is already entering its final phase
of development and could be available in some African countries as
early as next year.
Both partners have contributed towards the costs of product
development and have set up a joint team to oversee the development
product. Other important supporters of this initiative include the UK
Department for International Development (DfID) and the University of
"GlaxoSmithKline firmly believes that the complex issues associated
with meeting the healthcare needs of developing countries will only
be resolved through collaborative effort," said Jean-Pierre Garnier,
Chief Executive Officer, GlaxoSmithKline.
"The LAPDAP programme further demonstrates this new company's
determination to play its part in improving healthcare world-wide and
finding innovative and practical ways of providing much needed new
medicines to people in developing countries."
Dr Gro Harlem Brundtland, Director General of the World Health
Organization said: "Drug resistance means that large populations in
many parts of the world are without protection from malaria. LAPDAP
will be an important help in reducing the burden of malaria among
those living in Sub-Saharan Africa and elsewhere. This agreement
shows that public-private partnerships can achieve important
practical results. It is an important collaboration not only because
will bring a new drug to the market, but also because it includes a
price structure that aims at making the drug affordable for those who
WHO, by means of its UNDP/World Bank/WHO Special Programme for
Research and Training in Tropical Diseases (TDR), is arranging and
providing considerable financial support for clinical trials of
In addition, WHO is making available its technical expertise,
especially in the area of malaria clinical trials, to the development
team. TDR's expertise and the knowledge and experience of the WHO-led
"Roll Back Malaria" partnership will also be available as the
programme proceeds beyond regulatory approval.
GlaxoSmithKline will be responsible for product registrations and
manufacture of LAPDAP. The company will also commercialise the
product in the private sector according to standard local market
The UK Department for International Development (DfID) provided
funding to advance the project while the University of Liverpool, UK,
devised the concept of LAPDAP in the early 1990s, and have continued
to be major contributors to the programme. The Product Development
is chaired by Professor Peter Winstanley of The University of Liverpool.
The partnership intends to extend their collaboration to develop
LAPDAP in combination with an artemisinin derivative, in order to
extend further the useful life of the new medication.
Malaria is a serious, sometimes fatal, disease. At least 300 million
clinical cases occur world-wide every year, 90 percent of which are
in Africa. Every day close to 3000 people, mostly children under
five, die as a result of this disease.
Reprinted under the fair use doctrine of international copyright law:
Send mail for the `E-Drug' conference to `email@example.com'.
Mail administrative requests to `firstname.lastname@example.org'.
For additional assistance, send mail to: `email@example.com'.